MEDIAN to take part to the Imaging in Cancer Drug Development Conference (March14-15, 2012, London)

Sophia Antipolis, France

MEDIAN Technologies (ALMDT), a leading services provider for images interpretation and management during oncology clinical trials and software provider for medical imaging,  announces its participation as sponsor to the 8th Annual Imaging in Cancer Drug Development Conference, to be held next March 14-15th in London, UK.

During this conference, MEDIAN Technologies will make a presentation entitled “Toward better imaging interpretation and management to leverage oncology clinical trial success rates”. Today, images are used as surrogate endpoints in cancer drug development but their prominent role triggers new clinical and technological challenges ; the presentation will deal with the leading role of medical images in oncology clinical trials and will emphasize the significance of an optimized image interpretation and management workflow in this therapeutic area.

MEDIAN Clinical Trial Imaging Services (CTIS) offer as well as MEDIAN Lesion Management Solutions (LMS) portfolio will be presented on the MEDIAN booth during the conference.

The Imaging in Cancer Drug Development conference allows pharmaceutical companies, biotechnology companies and imaging CRO to review imaging practices and emergent technologies which enable to optimize oncology clinical trials.

Download Imaging_drug_development.pdf

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”


MEDIAN Technologies

Fredrik Brag
+33 4 92 90 65 82

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66